VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2021 | DESTINY-Gastric02: 2L T-DXd in HER2+ gastric cancers

Geoffrey Ku, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the results of the Phase II DESTINY-Gastric02 study (NCT04014075) presented at this years European Society for Medical Oncology (ESMO) 2021 congress. In this study, second-line trastuzumab deruxtecan (T-DXd) in Western patients with HER2-positive gastric/gastroesophageal junction cancer demonstrated clinical efficacy and a manageable safety profile. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter